BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87-113. [PMID: 18613831 DOI: 10.1111/j.1600-065X.2008.00628.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Kraemer M, Kirschmeier A, Marth T. Perioperative adjuvant therapy with infliximab in complicated anal crohn’s disease. Int J Colorectal Dis 2008;23:965-9. [DOI: 10.1007/s00384-008-0500-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
3 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
4 Zierhut M, Abu El-asrar AM, Bodaghi B, Tugal-tutkun I. Therapy of Ocular Behçet Disease. Ocular Immunology and Inflammation 2014;22:64-76. [DOI: 10.3109/09273948.2013.866257] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
5 Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87-113. [PMID: 18613831 DOI: 10.1111/j.1600-065x.2008.00628.x] [Cited by in Crossref: 653] [Cited by in F6Publishing: 321] [Article Influence: 50.2] [Reference Citation Analysis]
6 Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28:76-87. [PMID: 18410558 DOI: 10.1111/j.1365-2036.2008.03709.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
7 Einarson TR, Bereza BG, Ying Lee X, Lelli F. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Current Medical Research and Opinion 2017;33:1433-49. [DOI: 10.1080/03007995.2017.1335001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lönnkvist MH, Befrits R, Lundberg JO, Lundahl J, Fagerberg UL, Hjortswang H, van Hage M, Hellström PM. Infliximab in clinical routine: experience with Crohnʼs disease and biomarkers of inflammation over 5 years: . European Journal of Gastroenterology & Hepatology 2009;21:1168-76. [DOI: 10.1097/meg.0b013e32832b125c] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nazareth N, Magro F, Silva J, Duro M, Gracio D, Coelho R, Appelberg R, Macedo G, Sarmento A. Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection. Clin Exp Immunol 2014;177:703-11. [PMID: 24816497 DOI: 10.1111/cei.12375] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
10 Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm. 2009;24:321-325. [PMID: 19538054 DOI: 10.1089/cbr.2008.0607] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 6.6] [Reference Citation Analysis]
11 Uslu N, Usta Y, Saltik-Temizel IN, Demir H, Gürakan F, Ozen H, Yüce A. Ineffectiveness of infliximab therapy in severe infantile Crohn's disease. J Crohns Colitis 2010;4:106-9. [PMID: 21122492 DOI: 10.1016/j.crohns.2009.08.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:45-52. [PMID: 26395534 DOI: 10.1586/17474124.2015.1091308] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
13 Kawaguchi T, Kawazoe Y, Kamoi K, Miyanaga M, Takase H, Sugita S, Mochizuki M. Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58:75-80. [PMID: 24129677 DOI: 10.1007/s10384-013-0283-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
14 Salido Olivares M, Loza Santamaría E. Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: Systematic review. Semin Arthritis Rheum 2022;:151944. [PMID: 35027247 DOI: 10.1016/j.semarthrit.2021.11.010] [Reference Citation Analysis]
15 Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis 2021;15:840-59. [PMID: 32915970 DOI: 10.1093/ecco-jcc/jjaa186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
17 Annaházi A, Molnár T. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract 2015;2015:832395. [PMID: 26199624 DOI: 10.1155/2015/832395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
18 Alfawaz A, Alrashidi S, Kalantan H, Al-Mezaine H, Abu AM. Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet disease. Ann Saudi Med 2014;34:328-33. [PMID: 25811206 DOI: 10.5144/0256-4947.2014.328] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, Cheon JH. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019;34:1727-35. [PMID: 30851117 DOI: 10.1111/jgh.14652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
20 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
21 Vietri MT, Riegler G, De Paola M, Simeone S, Boggia M, Improta A, Parisi M, Molinari AM, Cioffi M. I219V polymorphism in hMLH1 gene in patients affected with ulcerative colitis. Genet Test Mol Biomarkers 2009;13:193-7. [PMID: 19371218 DOI: 10.1089/gtmb.2008.0088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
22 Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7:77-90. [PMID: 30976420 DOI: 10.1093/gastro/goz004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
23 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
24 Adán A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, Sanmartí R. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions. Int Ophthalmol 2010;30:577-81. [DOI: 10.1007/s10792-010-9372-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
25 Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182. [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 9.5] [Reference Citation Analysis]
26 Sochal M, Krzywdzińska M, Gabryelska A, Talar-Wojnarowska R, Małecka-Panas E. Efficiency and safety of one-year anti-TNF-α treatment in Crohn's disease: a Polish single-centre experience. Prz Gastroenterol 2020;15:156-60. [PMID: 32550949 DOI: 10.5114/pg.2019.90079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Rocha C, Lago P, Fernandes S, Correia L, Portela F, Vieira AI, Patita M, Arroja B, Ministro P, Alves C, Dias CC, Magro F. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. Therap Adv Gastroenterol 2020;13:1756284820965790. [PMID: 33281935 DOI: 10.1177/1756284820965790] [Reference Citation Analysis]
28 Nishida Y, Hosomi S, Watanabe K, Watanabe K, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Yamagami H, Tanigawa T, Watanabe T, Fujiwara Y. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scand J Gastroenterol 2018;53:579-85. [PMID: 29171305 DOI: 10.1080/00365521.2017.1403647] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
29 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
30 Gisbert JP, Marín AC, Chaparro M. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol 2016;111:632-47. [PMID: 27002797 DOI: 10.1038/ajg.2016.54] [Cited by in Crossref: 86] [Cited by in F6Publishing: 71] [Article Influence: 14.3] [Reference Citation Analysis]
31 Al Rashidi S, Al Fawaz A, Kangave D, Abu El-asrar AM. Long-term Clinical Outcomes in Patients with Refractory Uveitis Associated with Behçet Disease Treated with Infliximab. Ocular Immunology and Inflammation 2013;21:468-74. [DOI: 10.3109/09273948.2013.779727] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
32 Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201-211. [PMID: 21484965 DOI: 10.1002/ibd.21697] [Cited by in Crossref: 133] [Cited by in F6Publishing: 119] [Article Influence: 12.1] [Reference Citation Analysis]
33 Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology. 2015;149:1716-1730. [PMID: 26381892 DOI: 10.1053/j.gastro.2015.08.055] [Cited by in Crossref: 119] [Cited by in F6Publishing: 109] [Article Influence: 17.0] [Reference Citation Analysis]
34 Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience. Journal of Crohn's and Colitis 2012;6:143-53. [DOI: 10.1016/j.crohns.2011.07.011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
35 Worbes-Cerezo M, Nafees B, Lloyd A, Gallop K, Ladha I, Kerr C. Disutility Study for Adult Patients with Moderate to Severe Crohn's Disease. J Health Econ Outcomes Res 2019;6:47-60. [PMID: 32685579 DOI: 10.36469/9685] [Reference Citation Analysis]
36 Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42:391-405. [PMID: 26075832 DOI: 10.1111/apt.13276] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]